Who owns Inhibikase Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of IKT from SEC Form 13F filings across 104 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 104 institutions disclosed 116.1M shares of Inhibikase Therapeutics, Inc. worth $235.6M — about 66.5% of shares outstanding; the largest disclosed holder is Sands Capital Alternatives, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
104
13F holders
$235.6M
value, 2026 filers
66.5%
of shares outstanding (116.1M sh)
18
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of IKT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 13.0M | $26.4M | 4.3% | 7.5% | 0.0% |
| 2 | Soleus Capital Management, L.P. | 10.9M | $22.1M | 0.8% | 6.2% | 0.0% |
| 3 | Trails Edge Capital Partners, LP | 9.1M | $18.4M | 2.9% | 5.2% | +12.3% |
| 4 | Fairmount Funds Management LLC | 8.6M | $17.5M | 1.2% | 4.9% | 0.0% |
| 5 | BlackRock, Inc. | 7.8M | $15.8M | 0.0% | 4.4% | +23.2% |
| 6 | ADAR1 Capital Management, LLC | 7.4M | $15.0M | 0.7% | 4.2% | +11.8% |
| 7 | Blackstone Inc. | 5.9M | $12.1M | 0.0% | 3.4% | 0.0% |
| 8 | Siren, L.L.C. | 5.8M | $11.9M | 0.2% | 3.4% | 0.0% |
| 9 | Commodore Capital LP | 5.4M | $11.0M | 0.7% | 3.1% | 0.0% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 4.9M | $10.0M | 0.0% | 2.8% | +10.9% |
| 11 | MILLENNIUM MANAGEMENT LLC | 4.0M | $8.2M | 0.0% | 2.3% | +37.6% |
| 12 | Saturn V Capital Management LP | 3.9M | $7.9M | 1.1% | 2.2% | +0.1% |
| 13 | Kalehua Capital Management LLC | 3.8M | $7.8M | 5.6% | 2.2% | +43.0% |
| 14 | Spruce Street Capital LP | 3.6M | $7.3M | 1.4% | 2.1% | 0.0% |
| 15 | Squadron Capital Management LLC | 3.0M | $6.1M | 1.9% | 1.7% | -14.3% |
| 16 | Nantahala Capital Management, LLC | 2.7M | $5.5M | 0.2% | 1.5% | 0.0% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $5.3M | 0.0% | 1.5% | +20.1% |
| 18 | STATE STREET CORP | 1.9M | $3.9M | 0.0% | 1.1% | +13.2% |
| 19 | Integral Health Asset Management, LLC | 1.4M | $2.7M | 0.1% | 0.8% | 0.0% |
| 20 | NORTHERN TRUST CORP | 878,585 | $1.8M | 0.0% | 0.5% | +22.2% |
| 21 | VANGUARD PORTFOLIO MANAGEMENT LLC | 809,490 | $1.6M | 0.0% | 0.5% | +31.0% |
| 22 | TWO SIGMA INVESTMENTS, LP | 806,264 | $1.6M | 0.0% | 0.5% | -4.9% |
| 23 | SPHERA FUNDS MANAGEMENT LTD.NEW | 649,309 | $1.3M | 0.2% | 0.4% | new |
| 24 | VANGUARD FIDUCIARY TRUST CO | 607,260 | $1.2M | 0.0% | 0.3% | +7.1% |
| 25 | Kennondale Capital Management LLCNEW | 565,983 | $1.1M | 0.8% | 0.3% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.